Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]DK222 PET/CT Imaging in NSCLC and Urothelial Cancer
NCT07140315Phase 1Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2027
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]DK222 in non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Adverse Events at 10 days. Planned start Jan 2027; status: recruiting.
02
Drugs
[18F]DK222
03
Conditions
non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07140315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140315.